Medical Simulation Medical Graphic
Medical Animation | Mechanism of Action | Medical Print Illustration | Holo 3D | General 3D | Contact

Cell Animation


Custom flash 3d medical animation


Cell death animations and cell illustrations Medical Animation Studio produces custom 3d medical animations and custom 3d medical illustration.  MOA can be converted into flash medical animations for medical websites demonstrations.  PDA animations, Flash medical animated method of action videos. 
Brain Deletion Of FK506-Binding Protein Enhances Repetitive Behaviors In Mice
A new study reveals a link between dysregulation of a common signaling pathway and repetitive behaviors similar to those associated with multiple neurological and neurodegenerative disorders including, autism spectrum disorders, obsessive compulsive disorder, schizophrenia, and Huntington's disease.
Participants In Clinical Trials Should Be Viewed As Partners In Research
While an estimated 2.3 million people in the United States take part in clinical trials every year, there currently exists no formal requirement to inform them of study results, an oversight that leaves participants confused, frustrated, and, in some cases, lacking information that may be important to their health.
Novel Histone Demethylase Protein Complex Discovered By Researchers At Stowers Institute's Workman Lab
The Stowers Institute's Workman Lab has discovered a novel histone demethylase protein complex characterized in work published in Molecular Cell. The Histone H3 protein is an important component of chromatin, the packing material wrapping up chromosomal DNA and preventing unwanted transcription of the message encoded in the DNA. Histone H3 can be altered by adding (methylating) or removing (demethylating) methyl groups from the histone protein.
Cambridge Laboratories Announces Launch Of XENAZINE(R) (Tetrabenazine) In The US
Cambridge Laboratories Group Limited ("Cambridge"), the privately-owned specialty pharmaceutical company, today announces that XENAZINE(R) (tetrabenazine), the first and only product approved for the treatment of chorea associated with Huntington's disease, has been launched in the US.
'Deranged Calcium Signaling' Contributes To Neurological Disorder, UT Southwestern Researchers Find
Defective calcium metabolism in nerve cells may play a major role in a fatal genetic neurological disorder that resembles Huntington's disease, researchers at UT Southwestern Medical Center have found in a mouse study. The disease, called spinocerebellar ataxia 3 - also known as SCA3, or Machado-Joseph disease - is a genetic disorder that, like Huntington's, impairs coordination, speech, and vision and causes brain atrophy.
Chorea Associated With Huntington's Disease Ovation - Nationwide Availability Of Xenazine (tetrabenazine) Tablets In U.S.
OVATION Pharmaceuticals, Inc. announced today that Xenazine* (tetrabenazine) Tablets, an orphan drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of chorea associated with Huntington's disease (HD), is now available throughout the United States. Xenazine is the first and only FDA-approved treatment specifically developed for any HD-related symptom.
New Clue Emerges For Cellular Damage In Huntington's Disease
"Huntington's disease presents an ideal vantage point to study neurodegenerative disease, because we know the misfolded protein that's responsible," says Martin Duennwald, formerly a postdoctoral researcher in the lab of Whitehead Member Susan Lindquist. "But we don't understand how this protein causes cellular damage and death for the neurons that are affected.
Raptor Pharmaceuticals To Collaborate With Centre Hospitalier Universitaire D'Angers For Phase II Clinical Trial In Huntington's Disease
Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), announced that the Company has entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate Raptor's proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in a Phase II clinical trial in patients with Huntington's Disease ("Huntington's").
2008 Horwitz Prize Awarded To Arthur Horwich & Ulrich Hartl For Cellular Protein Folding
Columbia University will award the 2008 Louisa Gross Horwitz Prize to F. Ulrich Hartl, M.D., professor and director of the Department of Cellular Biochemistry at the Max Planck Institute of Biochemistry in Germany, and Arthur Horwich, M.D.
Antioxidants Could Help Huntington's Disease Sufferers
Therapeutic strategies to strengthen antioxidant defences could help to prevent the progression of Huntington's Disease. This is the suggestion from the results of the first ever trial on human samples carried out by researchers at the University of Lleida. The results have been published in the latest issue of Free Radical Biology & Medicine magazine.
Structure Of Important Neurological Receptor Defined By Scripps Research Scientists
Findings establish a platform to understand G protein-coupled receptors; may help in development of new class of Parkinson's treatments Scientists from The Scripps Research Institute have determined the structure of an adenosine receptor that plays a critical role in a number of important physiological processes including pain, breathing, and heart function.
Compounds That Prevent Nerve Damage Discovered By Duke Team
Duke University Medical Center scientists have made a significant finding that could lead to better drugs for several degenerative diseases including Huntington's disease and Alzheimer's disease. Compounds that block the activity of a specific enzyme prevented brain injury and greatly improved survival in fruit flies that had the same disease process found in Huntington's disease.
Repligen Announces Publication Of Positive Results With Proprietary HDAC Inhibitor In Huntington's Disease Model
Repligen Corporation (Nasdaq: RGEN) reported publication of a preclinical study demonstrating that a novel histone deacetylase (HDAC) inhibitor improved disease symptoms in a transgenic animal model of Huntington's disease. The study, led by scientists at The Scripps Research Institute, demonstrated that oral administration of the drug candidate to the mice after the onset of symptoms slowed the progression of disease.
Pfizer And Medivation Agreement To Co-Develop And Market Dimebon For Alzheimer's And Huntington's Diseases Treatment
Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for treatment of Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial in patients with mild-to-moderate Alzheimer's disease (http://www.connectionstudy.
News Tips From The Journal Of Neuroscience
PCP2 Shapes Light Response of ON Bipolar Cells Ying Xu, Pyroja Sulaiman, Rod Feddersen, Jian Liu, Robert G. Smith, and Noga Vardi Activation of G-protein-coupled receptors (e.g., metabotropic glutamate receptors in retinal ON bipolar cells) causes GTP to bind to the G-protein in place of GDP, resulting in dissociation and activation of Gα and Gβγ subunits and subsequent downstream effects (e.g., closing of cation channels).
WindowsFlashQuicktime
Request Demo Reel DVD
Related Medical Animation Links

Copyright © 2007
Content Management / Website Design by Tresware